Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With or Without Trastuzumab in Patients With 'Traditional' and 'Non-Traditional' HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy

Next Previous
X
Search
Trial Profile

Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With or Without Trastuzumab in Patients With 'Traditional' and 'Non-Traditional' HER2 Expressing Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MM 111 (Primary) ; Paclitaxel; Trastuzumab
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors Merrimack Pharmaceuticals

    • Most Recent Events

    • 03 Mar 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
    • 26 Feb 2015 Status changed from active, no longer recruiting to discontinued, according to a Merrimack media release.
    • 26 Feb 2015 According to a Merrimack media release, the company has decided to stop enrolment in this trial, due to recommendation from the Data Safety Monitoring Board (DSMB) for closure of the trial to further patient enrolment due to shorter progression free survival on the experimental arm relative to the control arm in the overall patient population.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top